Drug Trial Radar · NCT04519619
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Nov 27, 2020
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Aug 19, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).
Conditions
- Neovascular Glaucoma
Interventions
Aflibercept (Eylea, BAY86-5321)Drug
Administration by intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of participants with adverse events (AEs)Time frame: Up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Many locations
Multiple Locations, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.